Deal facts
- Buyer
- TCGX Acquisition Corp.
- Target
- TriGemX Bio, Inc.
- Deal value
- USD 361,000,000
- Announced
- 18 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
TCGX Acquisition Corp. has agreed to acquire TriGemX Bio, Inc. in a strategic transaction valued at 361 million US dollars. The deal, announced on 18 October 2026, involves the exchange of shares as the sole form of consideration. TCGX Acquisition Corp. is incorporated in the Cayman Islands, while the target company, TriGemX Bio, operates in the United States. Both entities are situated within the healthcare sector. The transaction represents a significant consolidation of assets within this industry, with the equity value serving as the primary metric for the deal’s scale. No completion date has been reported to date, and the process remains in the firm intention stage. The structure indicates a straightforward acquisition where the buyer assumes control through share issuance. This move positions the combined entity to leverage existing resources within the healthcare landscape. The specific terms regarding post-closing integration or operational changes have not been detailed in the available data. The transaction is subject to regulatory approval.
Deal timeline
1 update- Firm intention
TCGX Acquisition Corp. firm intention to acquire TriGemX Bio, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On October 18, 2026, TCGX Acquisition Corp., a Cayman Islands exempted company (“ TCGX ”), TriGemX Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of TCGX (“ Merger Sub ”), and TriGemX Bio, Inc. (formerly known as Kallyope, Inc.), a Delaware corporation (“ TriGemX ”), entered into a Business Combination Agreement
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
TCGX Acquisition Corp.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive